About ThromboDx
ThromboDx is a Healthcare company based in Amsterdam (Netherlands) founded in 2012, and was acquired by Illumina in January 2016. Its focus areas include Life Sciences, Oncology, In-Vitro Diagnostic Tests and Diversified.
Company details
Provider of blood platelet-powered molecular diagnostics tests. The company is mainly focusing on three markets Cancer Diagnostics, Infectious Disease Monitoring, and Prenatal Testing. The RD team of the company works in collaborations with several research groups including Cancer Center Amsterdam, the University of Umea in Sweden, and Harvard Medical School and Massachusetts General Hospital in Boston. The company is actively looking for partners for the co-development of platelet-powered prenatal diagnostics and infectious diagnostic tests. The company has received two EUROSTARS grants for developing a non-invasive test to monitor the dynamic mutational status of NSCLC patients for personalized medicine and a novel diagnostic assay to satisfy lung cancer patients with EGFR therapy resistance.
- Headquarters Amsterdam, Netherlands
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website thrombodx.nl
- Social X
- Acquired by Illumina (Jan 2016)
Funding Insights of ThromboDx
- Total Rounds 1
All 1 funding rounds of ThromboDx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2012 | Grant | – | – | – |
1 investors in total: 1 institutional.
Investors in ThromboDx
ThromboDx has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Illumina.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Developer of technologies for analysis of genetic variation and function | 1993 | illumina.com | San Diego, United States |
Investor details for ThromboDx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of ThromboDx
3 dated milestones of ThromboDx across 4 years, from founding to its latest funding, stage changes and deals.
- Founded ThromboDx is founded.
- Funding First funding round.
- Exit Acquired by Illumina.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about ThromboDx
ThromboDx was founded in 2012.
ThromboDx is headquartered in Amsterdam, Netherlands.
Provider of blood platelet-powered molecular diagnostics tests. The company is mainly focusing on three markets Cancer Diagnostics, Infectious Disease Monitoring, and Prenatal Testing. The RD team of the company works in collaborations with several research groups including Cancer Center Amsterdam, the University of Umea in Sweden, and Harvard Medical School and Massachusetts General Hospital in Boston. The company is actively looking for partners for the co-development of platelet-powered prenatal diagnostics and infectious diagnostic tests. The company has received two EUROSTARS grants for developing a non-invasive test to monitor the dynamic mutational status of NSCLC patients for personalized medicine and a novel diagnostic assay to satisfy lung cancer patients with EGFR therapy resistance.
ThromboDx has 1 investor. Key investors include Illumina.
Yes. ThromboDx was acquired by Illumina in January 2016.